BioPharmSignal logoBioPharmSignal

Biotech News

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

UroGen Pharma (URGN)UroGen PharmaCompany update

PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S.

Related news

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

URGNUroGen Pharma2026-09-04 12:00 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TEVATeva Pharmaceutical Industries2026-10-02 12:00 EST

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

RVMDRevolution Medicines2026-10-05 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

CGEMCullinan Therapeutics, Inc.2026-10-01 23:30 EST

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

FATEFate Therapeutics2026-09-16 11:00 EST

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

RVMDRevolution Medicines2026-09-14 20:05 EST

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

View all latest news

UroGen Pharma

Uro-Oncology Franchise UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease. Commercial ZUSDURI...

Recent company news

URGNUroGen Pharma2026-09-04 12:00 EST

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

URGNUroGen Pharma2026-09-02 12:00 EST

UroGen Pharma to Present at Upcoming Investor Conferences

URGNUroGen Pharma2026-08-20 11:00 EST

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

URGNUroGen Pharma2026-08-17 12:00 EST

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

URGNUroGen Pharma2026-08-05 12:00 EST

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Stock data

Close
40.55 USD
Market cap
1.29B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States